The company had been nominally out in front among developers of Tim3-targeted drugs, slightly ahead of GSK and partner AnaptysBio with cobolimab, which is being tested alongside GSK’s PD-1 ...

Previous studies have identified TIM3 (T-cell immunoglobulin domain and mucin domain 3) as a negative regulator of T helper 1 (T H 1)-cell responses. Now, new research shows that TIM3 is also ...